NSF/FDA SIR: 3D Engineered Tissue Models for In Vitro Safety Testing of Nanoparticles
NSF/FDA SIR: 3D Engineered Tissue Models for In Vitro Safety Testing of Nanoparticles
批准号:
1237549
负责人:
Jan Stegemann
金额:
$10.53万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2014-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract#1237549StegemannThe goal of this 1-year Scholar-in-Residence project is to develop enhanced in vitro testing methods to rigorously evaluate the safety of nanoparticles, which are increasingly being used as components of medical devices. In response to this emerging need, the U.S. Food and Drug Administration (FDA) has initiated efforts to characterize the biological effects of nanoparticles. In particular, the Office of Science and Engineering Laboratories (OSEL) in the Center for Devices and Radiological Health (CDRH) has a strong interest in nanotechnology and evaluating nanotoxicity. The PI's lab at the University of Michigan (UMich) has a longstanding interest in characterizing cell function in well defined and consistent engineered tissues composed of cells embedded directly in a 3D protein matrix, and also has been working on cell-nanoparticle interactions in these systems. Such engineered tissues mimic important aspects of the 3D environment of native tissues, and therefore have the potential to provide information on nanoparticle biocompatibility that is not available from conventional 2D cultures or animal studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NSF/FDA SIR: Three-Dimensional In Vitro Modeling of Interactions Between Orthopedic Wear Particles, Biofilm, and Macrophages
-
批准号:1937689
-
项目类别:Standard Grant
-
资助金额:$9.9万
-
财政年份:2019
-
负责人:Jan Stegemann
-
依托单位:
NSF/FDA SIR: Impact of Mechanotransduction in Polymer Microparticle-Induced Macrophage Inflammation and Osteolysis
-
批准号:1743665
-
项目类别:Standard Grant
-
资助金额:$9.82万
-
财政年份:2018
-
负责人:Jan Stegemann
-
依托单位:
NSF/FDA SIR: 3D Cell Culture Models as Regulatory Tools for Screening Macrophage Responses to Polymer Wear Debris.
-
批准号:1641065
-
项目类别:Standard Grant
-
资助金额:$9.78万
-
财政年份:2016
-
负责人:Jan Stegemann
-
依托单位:
I-Corps: Matrix-Enhanced Delivery of Cell Therapy
-
批准号:1242421
-
项目类别:Standard Grant
-
资助金额:$5.0万
-
财政年份:2012
-
负责人:Jan Stegemann
-
依托单位:
国内基金
海外基金
FDA上市药物库筛选鉴定靶向治疗ARID1A缺陷型结直肠癌的合成致死效应及分子机制研究
-
批准号:82373165
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:李爱民
-
依托单位:
多维互质结构FDA雷达稀疏空时距自适应处理研究
-
批准号:61771317
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2017
-
负责人:阳召成
-
依托单位:
基于FDA标记畸胎瘤细胞联合人胎盘屏障体外模型建立中药胚胎毒性评价体系的研究
-
批准号:81573740
-
项目类别:面上项目
-
资助金额:63.0万元
-
批准年份:2015
-
负责人:宋殿荣
-
依托单位: